These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33001144)

  • 1. Association of Oxymetazoline Hydrochloride, 0.1%, Solution Administration With Visual Field in Acquired Ptosis: A Pooled Analysis of 2 Randomized Clinical Trials.
    Slonim CB; Foster S; Jaros M; Kannarr SR; Korenfeld MS; Smyth-Medina R; Wirta DL
    JAMA Ophthalmol; 2020 Nov; 138(11):1168-1175. PubMed ID: 33001144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials.
    Wirta DL; Korenfeld MS; Foster S; Smyth-Medina R; Bacharach J; Kannarr SR; Jaros MJ; Slonim CB
    Clin Ophthalmol; 2021; 15():4035-4048. PubMed ID: 34675472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid and Sustained Eyelid Elevation in Acquired Blepharoptosis with Oxymetazoline 0.1%: Randomized Phase 3 Trial Results.
    Bacharach J; Wirta DL; Smyth-Medina R; Korenfeld MS; Kannarr SR; Foster S; J Jaros M; Slonim CB
    Clin Ophthalmol; 2021; 15():2743-2751. PubMed ID: 34211263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of topical oxymetazoline on eyelid position, eye redness, and patient-reported eye appearance: A randomized controlled trial.
    Shoji MK; Markatia Z; Ameli K; Bayaraa M; Clauss KD; Ugradar S; Lee WW
    J Plast Reconstr Aesthet Surg; 2023 May; 80():66-74. PubMed ID: 36996503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case Report: Treatment of Myasthenic Ptosis with Topical Ocular Oxymetazoline.
    Cooper J; Yang D
    Optom Vis Sci; 2021 Nov; 98(11):1317-1320. PubMed ID: 34510144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial.
    Kircik LH; DuBois J; Draelos ZD; Werschler P; Grande K; Cook-Bolden FE; Weng E; Berk DR; Ahluwalia G
    J Drugs Dermatol; 2018 Jan; 17(1):97-105. PubMed ID: 29320594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Pharmacokinetics of Oxymetazoline Cream Following Topical Facial Administration for the Treatment of Erythema Associated With Rosacea.
    Kuang AW; DuBois J; Attar M; Ahluwalia G
    J Drugs Dermatol; 2018 Feb; 17(2):213-220. PubMed ID: 29462230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the Second REVEAL Trial.
    Baumann L; Goldberg DJ; Stein Gold L; Tanghetti EA; Lain E; Kaufman J; Weng E; Berk DR; Ahluwalia G
    J Drugs Dermatol; 2018 Mar; 17(3):290-298. PubMed ID: 29537447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
    Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL
    Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled, multicenter, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdominal laparoscopic surgery.
    Wininger SJ; Miller H; Minkowitz HS; Royal MA; Ang RY; Breitmeyer JB; Singla NK
    Clin Ther; 2010 Dec; 32(14):2348-69. PubMed ID: 21353105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study.
    Donnenfeld ED; Karpecki PM; Majmudar PA; Nichols KK; Raychaudhuri A; Roy M; Semba CP
    Cornea; 2016 Jun; 35(6):741-8. PubMed ID: 27055211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical Oxymetazoline for Fecal Incontinence in Patients with Spinal Cord Injury: A Double-Blind Randomized Controlled Crossover Study.
    Barak N; Gecse KB; Takács I
    Dis Colon Rectum; 2019 Feb; 62(2):234-240. PubMed ID: 30451757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes to Eye Whiteness and Eyelid/Brow Position With Topical Oxymetazoline in Aesthetic Patients.
    Ugradar S; Kim JS; Trost N; Parunakian E; Zimmerman E; Ameli K; Shoji MK; Lee WW
    Aesthet Surg J; 2022 May; 42(6):582-589. PubMed ID: 34962512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
    Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
    Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.
    Karpecki P; Depaolis M; Hunter JA; White EM; Rigel L; Brunner LS; Usner DW; Paterno MR; Comstock TL
    Clin Ther; 2009 Mar; 31(3):514-26. PubMed ID: 19393842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion.
    Vaidyanathan S; Williamson P; Clearie K; Khan F; Lipworth B
    Am J Respir Crit Care Med; 2010 Jul; 182(1):19-24. PubMed ID: 20203244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinically Relevant Reduction in Persistent Facial Erythema of Rosacea on the First Day of Treatment With Oxymetazoline Cream 1.0.
    Tanghetti EA; Dover JS; Goldberg DJ; Dhawan SS; Luo L; Berk DR; Ahluwalia G; Alvandi N
    J Drugs Dermatol; 2018 Jun; 17(6):621-626. PubMed ID: 29879249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinations of Pilocarpine and Oxymetazoline for the Pharmacological Treatment of Presbyopia: Two Randomized Phase 2 Studies.
    Price FW; Hom M; Moshirfar M; Evans D; Liu H; Penzner J; Robinson MR; Lee S; Wirta DL
    Ophthalmol Sci; 2021 Dec; 1(4):100065. PubMed ID: 36246939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
    Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
    Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.